oteseconazole · Mycovia Pharms · NDA 215888
Vivjoa
Earliest generic entry, as listed
17 Mar 2036
Blocked by patent: US 10414751, US 9840492.
Listed patents · 5 unexpired
| Patent | Claims | Expires |
|---|---|---|
| US 10414751 | drug substance, drug product · sets the listed date | 17 Mar 2036 |
| US 9840492 | drug substance, drug product · sets the listed date | 17 Mar 2036 |
| US 11247981 | use U-3366 | 9 May 2033 |
| US 8236962 | drug substance, drug product | 22 Apr 2031 |
| US 8754227 | use U-3366 | 22 Apr 2031 |
Exclusivities · 2 unexpired
| GAIN | qualified infectious disease product | 26 Apr 2032 |
| NCE | new chemical entity (5 years) | 26 Apr 2027 |
Paragraph IV certifications · 0
No Paragraph IV certification listed by FDA for this drug.
The list shows that a generic applicant certified to FDA that a listed patent is invalid or not infringed. It does not show litigation, settlements or launch timing.
Event history
No events yet. The first ingestion only records products entering their 12-month window; changes appear from the next Orange Book update.
Products covered · 1
| NDA · product | Form | Strength | Listed expiry |
|---|---|---|---|
| 215888 · 001 · RLD | capsule, oral | 150MG | 17 Mar 2036 |